| GC31978-10mg |
|
91431-42-4 |
|
0 |
C16H15ClO6 |
|
|
|
| GC31978-5mg |
|
91431-42-4 |
|
0 |
C16H15ClO6 |
|
|
|
| GC31978-1mg |
|
91431-42-4 |
|
0 |
C16H15ClO6 |
|
|
|
| GC31977-50mg |
|
881179-06-2 |
α-2,3-sialyltransferase-IN-1
|
0 |
C28H45NO6 |
|
|
|
| GC31977-10mg |
|
881179-06-2 |
α-2,3-sialyltransferase-IN-1
|
0 |
C28H45NO6 |
|
|
|
| GC31977-5mg |
|
881179-06-2 |
α-2,3-sialyltransferase-IN-1
|
0 |
C28H45NO6 |
|
|
|
| GC31977-10mM(1mLinDMSO) |
|
881179-06-2 |
α-2,3-sialyltransferase-IN-1
|
0 |
C28H45NO6 |
|
|
|
| GC31976-20mg |
|
1096621-42-9 |
Anti-inflammatory agent 1
|
0 |
C17H16O3S |
|
|
|
| GC31976-10mg |
|
1096621-42-9 |
Anti-inflammatory agent 1
|
0 |
C17H16O3S |
|
|
|
| GC31976-5mg |
|
1096621-42-9 |
Anti-inflammatory agent 1
|
0 |
C17H16O3S |
|
|
|
| GC31976-1mg |
|
1096621-42-9 |
Anti-inflammatory agent 1
|
0 |
C17H16O3S |
|
|
|
| GC31975-100mg |
|
1030017-51-6 |
|
0 |
C19H15ClFNO2S |
|
|
|
| GC31975-50mg |
|
1030017-51-6 |
|
0 |
C19H15ClFNO2S |
|
|
|
| GC31975-25mg |
|
1030017-51-6 |
|
0 |
C19H15ClFNO2S |
|
|
|
| GC31975-10mg |
|
1030017-51-6 |
|
0 |
C19H15ClFNO2S |
|
|
|
| GC31975-5mg |
|
1030017-51-6 |
|
0 |
C19H15ClFNO2S |
|
|
|
| GC31974-20mg |
|
531506-36-2 |
A2B receptor antagonist 1
|
0 |
C21H24N6O2 |
|
|
|
| GC31974-10mg |
|
531506-36-2 |
A2B receptor antagonist 1
|
0 |
C21H24N6O2 |
|
|
|
| GC31974-5mg |
|
531506-36-2 |
A2B receptor antagonist 1
|
0 |
C21H24N6O2 |
|
|
|
| GC31974-1mg |
|
531506-36-2 |
A2B receptor antagonist 1
|
0 |
C21H24N6O2 |
|
|
|
